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ABSTRACT

SURVIVAL ANALYSIS WITH DNA METHYLATION USING ACCELERATED
FAILURE TIME MODEL AND LASSO
Wejdan Alhejaili, M.S.
Division of Statistics
Northern Illinois University, 2017
Dr. Duchwan Ryu, Director
This paper investigates the relationship between survival time and the methylation rate of DNA.
Inside the accelerated failure time model, Bayesian LASSO is utilized to analyze the different
methylation rates along with other covariates that significantly contribute in the interpretation of
the overall survival time.
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CHAPTER 1
INTRODUCTION
Many things affect the survival time of the DNA. To analyze the survival time, the use of
DNA methylation is very important; this process is part of the technology designed to give a
thorough output of genetic data (Akaike, 1974). The high-level technologies in the genetic data
analysis have to find their ways into various fields of genetics such as cancer studies, etymology,
and epigenetics. In this study, the relationship between survival time and DNA methylation is
analyzed and investigated, whereby the gene expression level is directly related to DNA
methylation, which implies that it is also associated with complex disease. Being present to regulate
the expression of genes, DNA methylation also ensures that a given gene is firmly silenced. DNA
methylation being part of the epigenetic process occurs when the methyl (CH3) group is added to
the DNA, and as a result, the normal function of the gene is modified. The addition takes place at
the 5-carbon specifically in the cytosine ring and therefore resulting in the formation of 5methylcytosine.
DNA is helpful in the understanding of the interactions occurring at the molecular level;
from there it will be very helpful in the clinical management and surgical operations of various
fatal malignant diseases and conditions (Alizadeh et al., 2000). DNA methylation can either be
next generation sequencing (NGS) data or microarray data; this analysis, however, is only focused
on the latter. Several challenges are however experienced in DNA methylation, and they include
the fact that DNA methylation might be present in way over 400,000 genetic sites, varying due to
technology. Another challenge can be experienced because the collection of DNA methylations
can encounter many errors. To ensure the workability of the survival model, considerations should

2

be made to guarantee error control and management. In a genetic region, survival model is
established by setting the predictor to be the DNA methylations from a given genetic pool; from
there a method based on the selection of variables is adopted. Survival data analysis has important
components, and they include response variable, censoring indicator and explanatory variable.
Survival analysis specifically takes the anticipated time to an event and uses it as a variable to
response; however, modeling of the survival time is not possible while using the linear regression,
mainly because of censoring which might occur because of many reasons like the individual's
withdrawal from a specified study (Breiman, 1996). Three types of censoring exist today: interval
censored, right censored and left censored (Figure 1). In survival data, the most common censoring
is right censored.
•

Interval censored occurs when one cannot determine the exact time but all we know is it
lies within an interval. For example, when individuals come to be examined every 6
months, those who are disease free at their first visit on their next visit may have the
disease. Then, all we know is that the disease has occurred at some time between visits.
This is considered interval censored.

•

Right censored occurs when some individuals live beyond the time of our study or they
drop out of the study, so all we know is that they were free of the event until a certain time.

•

Left censored occurrs when the individual already has the event before they enter the study.
However, we do not know since when they have it had it.
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Figure 1 Dataset with uncensored, right-censored and left-censored survival times.
Missing data may bring biases to the results, and they are mainly caused by bad ways of
handling censoring data which often end up being deleted. In this case, deletion occurs on the data
points experiencing problems. When it comes to survival, the point of interest is elaborating the
relationship between the factors of importance such as treatment, the time in which a specific event
is expected to occur and the presence of covariates such as age and gender. Many factors or models
are available when it comes to analysis of the existing relationship between survival time and
variables present in the predictor. The approaches involved include parametric, nonparametric and
semiparametric, whereby the initial approach assumes that the survival duration goes along the
distribution of probability based on parameters that are fixed. Nonparametric approaches are only
initiated when the life situations are unknown, so there is no necessity for any distribution
assumptions (Egger et al., 2004). The Kaplan-Meier estimator is mostly implemented in
nonparametric estimation, and it is mainly used when the rightcensored data is present. The most
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common semiparametric approaches is the Cox proportional hazard regression model, and it
combines both parametric and nonparametric models.
The most commonly used methods for acquiring predictions on survival mainly from highdimensional data are mainly aligned to the Cox proportional hazards (Cox, 1972). The accelerated
failure time has an important interpretation, mainly physical, which many times proves to be an
alternative to the earlier discussed Cox model in the analysis of survival time. The AFT model has
not seen a wide adoption mainly due to the complexities experienced in computing the algorithms.
However recently, AFT model has proven to be applicable in areas like the experimental aging
research; this fact is accelerated by the fact that there are many predictors in throughput data that
is high. When considering the DNA methylation rates, it is important to consider CpG locations as
enough predictors in the survival model and therefore it is important to select predictors that would
one way or another sum up to or exceed the total number of observations in contribution.
Apart from that, the method of performing variable selection is important in that it is critical
in statistics. Many researchers used the statistical methods of the past to find out the predictive
genes in n<p data only to find out that results obtained failed to be satisfactory enough and that
they only work in low-standard dimensions (Jin et al., 2003). The disadvantages of these models
have been upheld so as to contribute to the analysis of the failure time data that maybe one way or
another have covariates with relationships between them and the microarray gene expression.
Breiman proposed the LASSO motivation to shrink the estimates of OLS mainly by non-negative
factors while keeping the total of the said factors constrained. Bridge regression was introduced
around the same time LASSO was implemented; here a penalty notion was used instead of just
reducing the residual total of all squares (Kalbfleisch & Prentice, 2002). The penalty notion or
term λ is multiplied by the square of the norm belonging to the vectors β. The most popular is the
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smallest shrinkage possible together with LASSO. In the studies, the sample size is so big that the
number of gene goes to many thousands and so as to identify the various predictors for survival
times, variable selection methods have to be used.
In scenarios like this, the selection methodologies have only been recently developed. One
of the most known penalized model selection techniques used for reducing the coefficient is the
least absolute shrinkage and selection operator (LASSO). However, there have been many
improvements to it since it was introduced in 1996, whereby Pietrzykowski introduced the 𝑙1
penalty function through various research.
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CHAPTER 2
BACKGROUND OF THE STUDY
2.1 DNA Methylation
Every cell in the body of a human being has the same DNA sequence regardless of the vast
diversity in structure. The reason is mainly that all the cells in the body use specific genes. Mainly,
DNA can completely change or twist the expression of the gene by tagging itself to certain
chemicals, thereby making DNA methylation one type of epigenetic modification. To help in
maintaining silencing of genes, promotor DNA methylation connects to gene silencing. In the
human body, all types of cells have individual methylation patterns; these unique patterns are then
used to perform specified functions in the given cell (Figure 2.1.1). When it comes to a disease
like cancer, the DNA methylation patterns mentioned above are altered if not completely
disrupted.
There is a group of enzymes contained in the DNA methylation, and they are called DNA
methyltransferases (DNMT). DNMTs fall into three types: DMNT1, DNMT3a, and DNMT3b.
DNMT1 is the most widely present type of DNMT in adult cells (Robertson et al., 1999). It mainly
binds to the DNA with a single stand methylated; this binding usually occurs at the CpG sites.
After replication, however, the initial strands remain methylated while the strands being generated
do not. This maintains established CpG methylation patterns using the process of mitosis.
DNMT3a and DNMT3b on the other hand do not need the complex hemimethylated DNA so as
to glue. Instead, they portray equal affinity for both the hemimethylated and the nonmethylated
DNA. The main role of these two types of DNMTs is to allow for embryonic cell differentiation
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into many cell types. The promoter part of the DNA has its main role in the control of genetic
transcription. The DNA methylation causes the addition of a methy1(CH3) to the DNA strand
itself often to the fifth atom of a cytosine ring (Figure 2.1.2)

Figure 2.1.1. DNA methylation landscape.

Figure 2.1.2. DNA methylation.
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Human 10;11 translocation (TET) is critical in the regulation patterns, especially in
DNA methylation. It is performed by summing hydroxyl group to hydroxymethyl cytosine.
Epigenetic modifications are connected to DNA methylation in that they play a major role in
changing chromatin structure (see Table 2.1). Inactivity of specific types of tumorsuppressors often
result in hypermethylation; here, silencing of the transcriptional process slows down the various
growth regulators, and because they are part and parcel of hypermethylation, this often leads to the
development of cancer. Azacytidine and decitabine, which are both inhibitors, function in the
silenced genes in cancer, whereby they encourage the workability and reverse expression of the
abnormal gene which would one way or another result in a reduction of growth of cancer cells.

2.2 Survival Analysis
The main focus of survival analysis is on the time taken for some event to occur; it makes
inferences concerning rates of events being functions of a given time (Wei, 1992). Being the study
of distributions of given time to an initial event, it is also focused on the terminal event especially
when the end event is not certainly known. For a given time x , suppose the probability function
is ƒ(x) and the cumulative distribution function is
F(x) = p(T ≤ x)
Given the above equation, the probability of survival which is denoted by S(x) is calculated by:
𝑆(𝑥) = 𝑝(𝑇 > 𝑥) = 1 – 𝐹(𝑥)
Where

for x > 0,
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Table 2.1
Comparison Between Normal Cells and Cancerous Cells
Normal cells

Cancer cells

They are connected with other cells

They lose the molecules which help
maintain cells being bounded together

Control cells division and grow when too They do not stop growing leading to the
much of their types are appear.
appearance of tumor

Have equal sizes and shapes

Have many variety of sizes and shapes

Often communicate with each other

They do not communicate with each other

Transport a normal cell feature

Normal cell feature is absent

They mature to functional cells

They do not mature to become functional
cells.

This is also called the survival function where it is the possible that an event happens after
duration x. The probability of failure hazard function involves finding out the probability that a
given patient will pass away at time t, implying that the patient survived until time x (Lawless,
2003). This fact highlights conditional probability denoted by ℎ (𝑥) and it is described by equation
that
ℎ (𝑥) = 𝑓(𝑥)/𝑆(𝑥) = 𝑓(𝑥)/1 − 𝐹(𝑥)
Cumulative function on hazard denoted by 𝐻(𝑥)can also be calculated by the
equation
𝑡

𝐻(𝑥) = ∫ ℎ(𝑥) 𝑑𝑥, 𝑥 > 0.
0
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Given that
ℎ (𝑥) = − 𝜕 𝑙𝑜𝑔(𝑆(𝑥))/ 𝜕𝑡 𝑎𝑛𝑑 𝐻(𝑡) = −𝑙𝑛[1 − 𝐹(𝑥)] = − 𝑙𝑛(𝑆(𝑥))
then survival function (𝑆(𝑥)) is as follows:
S(x) = exp(−H(x))

2.2.1 Common Families of Survival Distributions
2.2.1.1Exponential Distribution
The most commonly used CDF for modelling is exponential distribution due to its
simplicity. Also known as negative exponential distribution, it is denoted by
𝑇 ∼ 𝐸𝑥𝑝(𝜆)
The common major assumption in negative exponential survival function that the rate is ever
constant:

h(x) = λ
H(x) = λ
Another survival function, in this case denoted by S(t), is

S(t) = exp{−λx}

Because 𝑥 > 0, probability density function (PDF; Figure 2.2.1) denoted by f(x) of this type of
distribution is calculated by
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𝑓(𝑥) = { λ𝑒
0

λt

𝑥≥0
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒

On the other hand, CDF (Figure 2.2.1) denoted by F(x) is expressed by

F(x) = 1 − exp {−λx }
if x
In this case, larger λ implies high risk and a shorter survival. The smaller λ basically implies
low levels of risk and long survival. The exponential distribution therefore lacks memory property,
meaning that the individual’s survival in the future is not affected by how long the individual has
survived previously . That said, the expression is
pr[X > 𝑥] = P[X > 𝑥 + 𝑠|X > 𝑠] for any s > 0

The exponential distribution contains only the scale parameter. To generalize this, one
can add a shape parameter, and by doing this addition, the distribution that comes out of the sum
up is called Weibull distribution.
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Figure 2.2.1. Exponential CDF and PDF .
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2.2.1.2 Weibull Distribution
This is a standardization of the exponential distribution. It is widely used in reliability
engineering because of its characteristic of being versatile and relatively simple. In this case,
assuming
T

W (λ, β)

Where β is the shape parameter, λ is the scale parameter. With probability density function (Figure
2.2.2) we can express this as
𝑓(𝑡) = 𝛽 𝜆𝛽𝑡𝛽 − 1 𝑒𝑥𝑝 {− ( 𝜆𝑡 )𝛽𝑡𝛽 − 1 𝑒𝑥𝑝 − (𝜆𝑡) 𝛽 },

𝛽 > 0 𝑎𝑛𝑑 𝜆 > 0

The cumlative distribution function (Figure 2.2.3) is therefore calculated by this equation:
𝐹(𝑡) = 1 − 𝑒𝑥𝑝 − (𝜆𝑡) 𝛽

𝑡 > 0

The hazard function denoted by h (t) is reached when the following equation is calculated:
ℎ(𝑡) = 𝛽 𝜆𝛽𝑡𝛽 − 1 (𝑝𝑜𝑤𝑒𝑟 𝑜𝑓 𝑡)
Elsewhere, the cumulative hazard function H (t) is expressed as
𝐻(𝑡) = ( 𝜆𝑡 )𝛽
Then the survival probability denoted by S(t) is reached by calculating the following
equation:
𝑆(𝑡) = 𝑒𝑥𝑝 {−( 𝜆𝑡 )𝛽 }
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Figure 2.2.2. Weibull probability density function.

Figure 2.2.3. Weibull cumulative distribution.
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A note should be taken that, when β = 1, the distribution of change from both Weibull to
exponential distribution, then the hazard function will be constant (Rosenwald, 2003). When β >
1 the hazard increases and when β < 1 then the given hazard goes down (Figure 2.2.4).

Figure 2.2.4. Weibull failure rate with 0 < 𝛽 < 1, 𝛽 = 1, 𝑎𝑛𝑑 𝛽 > 1.

2.2.1.3 Log-Normal Distribution
This is a type of distribution whose distributed logarithm is normally distributed. Lognormal distribution can model any natural phenomena (Figure 2.2.5), from simple attributes like
weight to complex phenomena like rainfall droplets.
In this case, modelling a random variable 𝑥 can be shown by the following equation:
𝑓(𝑥) = 1/(√2𝜋 𝜎) 𝑒𝑥𝑝{−1/(2𝜎2) (𝑙𝑜𝑔𝑥 − 𝜇)2 }

𝑥 > 0; 𝜎 > 0
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μ = β0 + β1x
where log(X) is distributed normally, implying that 𝑳𝒐𝒈 (𝑿) ~ 𝑵 (μ, 𝝈𝟐)with a density function.
Mathematically, the CDF is expressed like
𝐹(𝑥) = 𝛷(𝑙𝑛(𝑥)/𝜎)

𝑥 ≥ 0; 𝜎 > 0

From here it can be expressed in equation as
ℎ(𝑥 , 𝜎) = (1/𝑥 𝜎)𝜙(𝑙𝑛 𝑥/𝜎)/𝛷(−𝑙𝑛 𝑥/𝜎)

𝑥 > 0; 𝜎 > 0

Cumulative hazard function (CDF) is the most important aspect in hazard function. Here
it can be simplified as the possibility of failing at a given time x given survival until time 𝑥. CDF
of the log-normal distribution (figure 2.2.6) is:
𝐻(𝑥) = −𝑙𝑛(1 − 𝛷(𝑙𝑛(𝑥)/𝜎))

𝑥 ≥ 𝑜; 𝜎 > 𝑜

Survival distribution is the possibility that the variant carries a value bigger than 𝑥:
𝑆(𝑥) = 1 − 𝛷(𝑙𝑛(𝑥)𝜎)

𝑥 ≥ 0; 𝜎 > 0

where Φ(·) is CDF of standard normal. It is displayed much like the CDF (Jin et al., 2003). It is
often used for reliability and related fields to express possibility in which a unit survives beyond
time 𝑥.
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Figure 2.2.5 The log-normal probability.

Figure 2.2.6 Log-normal CDF.
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Survival analysis is a given collection of ways and methods of analyzing data whereby the
outcome is based on the time to an event which is being monitored. The time given is usually
considered as the survival time and this can be measured in years, weeks and even days. An
example can be that the event of interest is death from cancer; then the survival time can then be
measured in years until the person dies from cancer or symptoms associated with cancer. If an
event thereby occurred among all the individuals, appropriate methods will be used to analyze the
data. When follow-up of the stated individual ends and the event of interest has not happened, then
it will lead the researcher to the right-censored event times. What is generally in the back of the
minds of various researchers is that T exceeds U whereby U is the total follow-up time. Many
survival analyses on cancer patients have used either Kaplan-Meier plots, log-rank tests and Cox
concept. Being nonparametric, Kaplan-Meier and log-rank estimations cannot be assumed in terms
of mathematic calculations and therefore they leave Cox’s proportional hazard as one method
which can be assumed mathematically (Wei, 1992).
2.2.2 Cox Proportional Hazard
This is one of the mainly used models when it comes to the analysis of survival data. The
main principle of this model is that it links the overall survival time to covariates like gender and
age. This model helps in understanding the impacts of specific predictor variables and the
influence they have on getting to the event of interest given time is a factor to be considered.
Here, Cox model then assumes the hazard rate and bases it on the fact that it is a function of the
independent covariates. It however does not formulate any assumptions in the survival
distribution. Therefore, the hazard function at a given time can be represented as
h (t|x) = h0 (t) exp (β1X1+β2X2+.... +βPXP), t > 0
where ℎ (𝑋) is function denoting Hazard and t is the time.
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(x1 … … … … . xp) are the predictors.
(β1 + β2+. . . . +βP) is vector coefficients.
h0(t) is the baseline hazard.
Two important parts are included in the predicted hazard: the baseline hazard function denoted by
the function (h0 (t)) and the exponential function. The basis for measurement of change based on
every event is the baseline hazard function and it basically begins at start of covariates. Comparison
of the hazard functions for any two covariate values ( in this case i and j )can be done by using
hazard ratio, which is expressed by

h0(t) exp{βxi}
= exp{β(xi − xj)} for i ≠ j

HR =
h0(t) exp{βxj}

Because it does not require assignment of any type of distribution for survival time, the
proportional hazard model is considered to be the most promising model for analysis of survival
data. However, there is still a need to check for the assumption of proportional hazard model so
as to get a workable model; therefore, the hazard ratio above is just about constant (Akaike, 1974).
In this case, if the proportional hazard does not seem to hold, the most convenient model to be
used cannot be Cox and an alternative method for survival data analysis must be selected.
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2.2.3 Accelerated Failure Time
This is one of the many parametric models of analyzing survival data. Being related to
conventional linear regression, the model is most famous due to its aspect of relating covariates
to the survival time. AFT model goes along the fact that the effects of the several covariates
mainly function to accelerate or reduce the span of a disease by a given constant. The response
variable of this type of model is the logarithm of total time of being alive to the total number of
covariates present. Being a linear regression model, the formula can be expressed as
𝑌 = 𝑙𝑜𝑔 𝑇 = 𝑋′𝛽 + 𝜎 𝑍
Here Ti is the logarithm of the failure time.
X is the covariate vector.
′

𝛃 = (β1, … , βp) is the parameter vector while σ is the scale parameter.
Z is the normal random error, assuming that it follows a normal distribution.

2.3 LASSO Estimation for Censored Data
This model is best explained using the following expressions:
𝑦𝑖 = 𝑥𝑖′ 𝛽 + 𝑓𝑖,

( 𝑖 = 1, . . . , 𝑛)

Here yi is the natural logarithm of failure time variable, ithis the subject of the variable, the
unknown coefficient is β and these need to be estimated, and (fi, . . ., fn) are the independent and
identical distributed errors. In this highly dimensional situation, the least squares estimator of the
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coefficient is not easily identified. Directional methods like forward, stepwise and backward are
useful, but in this situation, they might work poorly (Breiman, 1996). The LASSO estimator then
estimates the coefficients in the expression mentioned above by reducing the residual sum of
squares and subjects to sum the total of squares subject to the sum of the absolute value of the
coefficient, which in this case is less than the constant. Let 𝛃 = (β1, … , βp)′ denote the vector of
regression of coefficients. LASSO finds he coefficient which minimizes the resulting sum of
square and the penalty termL1 , where
𝑚𝑖𝑛 (𝑦 − 𝑋𝛽)𝑡 (𝑦 − 𝑋𝛽) + 𝜆 𝛴 |𝛽𝑗|
Variables with non-zero regression coefficients are most strongly associated with the response
variable.
2.4 Bayesian LASSO
Considering the Bayesian LASSO, when a prior for β is described in terms of Gaussian,
both the mean and mode of the distribution that is posterior and corresponding to it can be defined
as the ridge estimate (Figure 2.4.1). LASSO depends on data for prediction; it also uses assumption
when it comes to selection of variables, and the final characteristic is that its shrinkage among
predictors is not smooth and happens to select only one additive of representation.
Bayesian LASSO’s implementation is easy and it automatically gives estimates for all
aspects, including variance of errors and mistakes. LASSO estimates can be clearly elaborated
andinterpreted when parameters of regression have similar and independent Laplacian priors. Take
for instance this expression:
𝑦 ∼ 𝑁 (𝑋𝛽, 𝐼𝑛) 𝑎𝑛𝑑 𝛽𝑖 ∼ (𝜆/ 2)𝑒𝑥𝑝 − 𝜆|𝛽𝑗|
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p

𝜋(𝛽) = Π

λ
2

ex−𝜆|𝛽𝑗|

j=1

The independent prior in this case is σ² , where Π (σ²) = 1/σ²

Figure 2.3.1 LASSO and ridge regression comparison.
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Normal prior places little or no weight at the point close to zero, unlike the Laplacian
prior (Figure 2.4.2). When considering analysis of the Bayesian LASSO using Laplacian prior,
which is conditional, the expression can be written as

𝑃

𝜋(𝛽|𝜎²) = 𝛱 (𝜆 /2 √ 𝜎²) exp − 𝜆|𝛽𝑗 |/ √ 𝜎²
j=1

In this case π(σ²) = 1/σ represents the scale-invariant which is improper and marginal.

Figure 2.4.2 Normal prior (…….) and the double exponential prior (

).
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CHAPTER 3
MODEL
3.1 The Accelerated Failure Time Model

The accelerated failure time model (AFT) is an alternative to the Cox proportional hazard
model (PH) for the analysis of survival time data. Under AFT models the direct effect of the
explanatory variables on the survival time is measured instead of hazard, as done in the PH model.
This characteristic allows for an easier interpretation of the results because the parameters
measure the effect of the correspondent covariate on the mean survival time. Currently, the AFT
model is not commonly used for the analysis of clinical trial data, although it is fairly common in
the field of manufacturing. Similar to the PH model, the AFT model describes the relationship
between survival probabilities and a set of covariates.
For a group of patients with covariate (𝑋1, 𝑋2, … , 𝑋𝑝) the model is written mathematically
as 𝑆(𝑡/𝑥) = 𝑆0(𝑡/𝜂(𝑥)) , where 𝑆0(𝑡) is the baseline survival function and 𝜂 is an acceleration
factor, which is a ratio of survival times corresponding to any fixed value of S(t). The acceleration
factor is given according to the formula:

𝜂(𝑥) = exp(𝛼1𝑥1 + 𝛼2𝑥2 + ⋯ + 𝛼𝑝𝑥𝑝).
Under an accelerated failure time model, the covariate effects are assumed to be constant and
multiplicative on the time scale; that is, the covariate impacts on survival by a constant factor
(acceleration factor). According to the relationship of survival function and hazard function, the
hazard function for an individual with covariate 𝑋1, 𝑋2, … , 𝑋𝑝 is given by
ℎ(𝑡/𝑥) = [1/𝜂(𝑥)]ℎ0[𝑡/𝜂(𝑥)]
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The corresponding log-linear form of the AFT model with respect to time is given by
𝑙𝑜𝑔𝑇𝑖 = 𝜇 + 𝛼1𝑥1 + 𝛼2𝑥2 + ⋯ + 𝛼𝑝𝑥𝑝 + 𝜎 𝑖
where 𝜇 is intercept, 𝜎 is scale parameter and 𝑖 is a random variable, assumed to have a particular
distribution. This form of the model is adopted by most software packages for the AFT model.
The AFT models are fitted using the maximum likelihood method. The likelihood of the
n observed survival times 𝑡1, 𝑡2, … , 𝑡𝑛 is given by
𝑛

𝐿(𝛼, 𝜇, 𝜎) = ∏{𝑓𝑖(𝑡𝑖)}𝛿𝑖{𝑆𝑖(𝑡𝑖)}1−𝛿𝑖
𝑖=1

where𝑓𝑖(𝑡𝑖) and 𝑆𝑖(𝑡𝑖) are the density and survival functions for the ith individual at t and 𝛿𝑖 Is the
event indicator for the ith observation. The log-likelihood function is then given by

𝑛

𝐿(𝛼, 𝜇, 𝜎) = ∑{−𝛿𝑖log( 𝜎𝑡𝑖 + 𝛿𝑖𝑙𝑜𝑔𝑓 𝑖(𝑧𝑖) + (1 − 𝛿𝑖)𝑙𝑜𝑔𝑆 𝑖(𝑧𝑖)}
𝑖=1

where 𝑧𝑖 = (𝑙𝑜𝑔𝑡𝑖 − 𝜇 − 𝛼1𝑥1𝑖 − 𝛼2𝑥2𝑖 − ⋯ − 𝛼𝑝𝑥𝑝𝑖)/𝜎. The maximum likelihood estimates of the
𝑝 + 2 unknown parameters 𝜇, 𝜎, 𝛼1, 𝛼2, … , 𝛼𝑝 are found by maximizing this function using the
Newton-Raphson procedure.
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3.2 The Bayesian LASSO
As it was already introduced in chapter 2, this research will concentrate on the application
of Bayesian LASSO of Park and Casella (2008). Although various other Bayesian LASSO
methods have been proposed recently, the Bayesian LASSO of Park and Casella (2008) is
appropriate for this study.
The model discussed above is constructed and represented as
𝑦=𝜇1𝑛+𝑋𝛽+

where y is the 𝑛x1 vector of responses (i.e. the survival time) given as 𝑦 = (𝑦1, … , 𝑦𝑛)𝑇, 𝜇 is the
overall mean, X is the nxp matrix of standardized regressors given as (𝑥1, 𝑥2 … , 𝑥𝑝)𝑇, 𝛽 = (𝛽1 …
𝛽𝑝)T is the vector of regression coefficients to be estimated and is the nx1 vector of independent
and identically distributed normal errors with mean 0 and unknown variance 𝜎2 represented
mathematically as ∈ ~𝑁𝑛(0, 𝜎2𝐼). The Bayesian approach has been in used in cases where p<n
and in a more common case with p>n. The estimate of 𝜇 is taken as the average of 𝑦 of the
responses, and the LASSO estimates 𝛽 which minimizes the sum of squared residuals, subject to
a given bound on its 𝐿1 norm. The entire part of Lasso estimates for all values of t can be
conveniently computed.
For values of t less than the 𝐿1 norm of the ordinary least squares estimate of 𝛽 LASSO
estimate can be described as solutions to unconstrained optimization of the form
𝑝

min(𝑦 − 𝑋𝛽)𝑇(𝑦 − 𝑋𝛽) + 𝜆 ∑ |𝛽𝑗|
𝛽
𝑗=1
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where 𝑦 = 𝑦 − 𝑦1𝑛 is the mean-centered response vector of survival time and the parameter 𝜆 =
0 relates implicitly to the bound t. The form of this expression suggests that the LASSO may be
interpreted as a Bayesian posterior mode estimate when the parameters 𝛽𝑖 have independent and
identical double exponential (Laplace) priors ( Hastie et al., 2001; Tibshirani, 1996). Indeed, with
the prior
p
𝜋(𝛽) = ∏ 𝜆/ 2 𝑒 −λ|βj|
𝑗=1

(1)

and an independent prior 𝜋(𝜎2) on 𝜎2 > 0, the posterior distribution conditional on 𝑦 can be
expressed as
𝑝

𝜋(𝛽, 𝜎2|𝑦)

|𝛽𝑗|}
j=1

Alternatively, this can be obtained as a conditional posterior for y if the 𝜇 can be obtained as an
independent prior and can be removed by marginalization.
Given a fixed value of 𝜎2> 0, then the maximizing 𝛽 can be regarded as a LASSO estimate.
Most importantly, the particular choice of the estimate will depend on the choice of 𝜎2 and 𝜆.
If we are to maximize the posterior which is sometimes convenient, then it is not a particularly
Bayesian way to obtain the point estimates, taking, for example, the posterior mode will not be
necessarily preserved under marginalization. But note that a full Bayesian analysis would instead
suggest using the mean or median of the posterior to estimate the coefficients 𝛽.
Though it can be confirmed that such estimates lack the model selection property of
LASSO, they do produce similar individualized shrinkage of the coefficients. But it can be
confirmed that the full Bayesian approach also provides credible intervals for the estimates, and
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with that we choose the 𝜆 using the marginal (Type-II) maximum likelihood or the hyper-prior
methods. Therefore, we can explain the conditional priors of the estimate of 𝛽 in the form

(𝛽|𝜎2) =

J=1

𝜆|𝛽 |

𝜆

∏

𝑒 √𝜎2
√

2

(2)

𝜎2

Instead of prior listed in equation (1). We can safely complete the prior specification with the
(improper) scale invariant prior 𝜋(𝜎2) = 1/𝜎2 .
3.3 Application
The Bayesian LASSO model discussed above will be used to investigate the relationship
between survival time and methylation rate of DNA using a sample of 89 patients obtained for the
year 2017. All patients are aged 38 to 84 years. The variables under study are discussed below:
Response: Survival Day- Time interval in days from the time of test to the date of observation,
both dates inclusive. Covariates: Status Indicator- Status: 1 = Cancer, 11 = Normal. Patients are
diagnosed for cancer; any patient who dies after the follow-up cut-off date is recoded to alive as
of the cut-off date. Patient loss to follow-up, with unknown disease outcomes, are recorded as
censored. Gender- MALE = Man, FEMALE = Woman. Stage- 1 = Cancer stage 1… 4 = Cancer
stage 4. Smoke15- 0 = lifetime nonsmoker, 1 = quit smoking more than 15 years, 2 = quit smoking
within 15 years, 3 = currently smoking. Age- Age of patient (all patients are aged 38 to 84 years).
Methylation Rate- Measured from 28 different CPG sites.
116381609: Methylation rate at CpG site 1
:
119671238: Methylation rate at CpG site 28
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CHAPTER 4
DATA ANALYSIS
4.1 Background of Analysis
The Bayesian LASSO of the AFT model fram work, the choice of regularizing, is
analogous to the choice of prior over the weight if a Gaussian prior is used for the covariates;
then the maximum a posteriori solution will be the same as if an 𝑙2 penalty was used.
The Bayesian LASSO of the accelerated failure time model is an approach to survival
time regression in which the analysis is undertaken within the context of Bayesian inference.
When the AFT model has errors that have a normal distribution, and if a particular form of prior
distribution is assumed,4.1 then explicit result will be available for the posterior probability
distributions of the model parameters. In a Bayesian context, this is equivalent to placing a
zeromean normally distributed prior on the parameter vector.
This chapter presents the analysis of the survival time data using the Bayesian LASSO
regression method. The principal aim of this analysis is to investigate the effect of methylation
rate on survival time of DNA, and the method of estimation was adapted from available literature
on the application of Bayesian LASSO regression to the AFT model.
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4.2 Exploratory Analysis
This research considers 89 observations and 34 predictors which comprise 28 methylation
CPG sites and six other predictors of the survival time of cancer patients, the goal being to
determine the relationship between the selected predictors and survival time of cancer patients.
Figure 4.1- 4.3 depict the characteristics of some of the variables considered in this research.

Density Plot of Survival Time
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Figure 4.1 Density plot of survival time.
Figure 4.1 displays the distribution of the survival time of cancer patients measured in
days, and as revealed by the plot, the peak of the density distribution is at about 0.6 at about 400
days survival time, which is an indication that 60% of the cancer patients under study survive
between 0 to 500 days and a constant low was observed 2000 days survival time and 3000 days
survival time, which maintain a constant probability value of about 0.02, indicating that about 2%
of the patients survived between 2000 to 3000 days.
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Density Plot of Patient Age
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Figure 4.2 Density plot of patient age.
Figure 4.2 displays the distribution of the age of cancer patients, and as revealed by the
plot, the peak of the density distribution is at about 0.5 at about 68 years, which is an indication
that 50% of the cancer patients under study are 68 years old.
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Figure 4.3 Box plot of selected clinical and demographical information of patients.
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Figure 4.4 displays the cumulative distribution function of the survival time of the cancer
patients under study and it can be confirmed from the plot that probability of surviving 1000 days
is less than 0.75. Therefore, by 1000 days, a patient has accumulated quite a bit of risk and it
continues to accumulate further after this point. In interval where event times are more probable
(here the beginning intervals), the cumulative distribution function will increase faster.

Cumulative Distribution Function of Survive Time
1.00

0.75

0.50

0.25

0.00
0

1000

2000

3000

SurvDay

Figure 4.4 The cumulative distribution function of survival time.
Figure 4.5 above is the Kaplan-Meier survival curve of the cancer patients after examining the
effect of the covariates and it can be concluded that the probability of surviving to 3000 days is
close to 1 as observed from the cumulative distribution function presented above.
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Kaplan- Meier Plot with confidence bands

Figure 4.5 The Kaplan-Meier survival curve.
Figure 4.6 presents the cumulative hazard function of the survival rate of cancer patients
under study. The plot was used to measure the total amount of risk that has been accumulated for
up to a particular time. From the plot, it can be predicted that there will be a constant increase in
the cumulative hazard at the end of follow-up time which is a reflection of a larger hazard rate
during the retrospective study.
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Figure 4.6 The cumulative hazard function.
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4.3 The Bayesian LASSO Regression for AFT Model
This section presents the result of analysis of the research data with the application of the
standard Bayesian LASSO performance in R. From the plots displayed above, it was revealed that
the survival time of the patients under study depends on some of the factors under study. Table 4.1
displays the summary of the Bayesian LASSO regression estimates.
Table 4.1
Summary of Bayesian LASSO Regression Estimates
Variable

Β

Std.Err

Pro of β = 0

Status

-0.3597

12.9999

0.492

Gender

2.3873

27.7802

0.472

Stage

-1.5553

19.8178

0.479

Smoke15

-2.4555

18.4099

0.486

Age

0.3311

7.9495

0.469

Methylation CPG Site 1

1.3748

13.2340

0.504

Methylation CPG Site 2

1.6210

16.6101

0.503

Methylation CPG Site 3

3.2676

23.5877

0.504

Methylation CPG Site 4

3.0836

18.2398

0.473

Methylation CPG Site 5

2.3984

15.3562

0.528

-0.0695

20.7933

0.485

Methylation CPG Site 6
(continued on following page)
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Table 4.1 continued
Methylation CPG Site 7

0.2115

13.4322

0.465

Methylation CPG Site 8

1.4794

18.2526

0.511

Methylation CPG Site 9

-2.4029

19.9209

0.493

Methylation CPG Site 10

1.5129

14.4698

0.497

Methylation CPG Site 11

1.6684

25.5833

0.476

Methylation CPG Site 12

3.9942

25.9001

0467

Methylation CPG Site 13

-2.6036

20.8516

0.493

Methylation CPG Site 14

1.5623

21.3319

0.481

Methylation CPG Site 15

1.9022

24.2709

0.488

Methylation CPG Site 16

3.7646

18.5186

0.531

Methylation CPG Site 17

-1.3656

16.7408

0.484

Methylation CPG Site 18

-6.3985

21.9505

0.486

Methylation CPG Site 19

0.3817

24.6729

0.531

Methylation CPG Site 20

-1.3093

20.3491

0.484

Methylation CPG Site 21

-2.4040

23.6373

0.486

Methylation CPG Site 22

-3.1562

27.5928

0.497

Methylation CPG Site 23

2.8244

43.2709

0.472

Methylation CPG Site 24

-1.7162

15.1968

0.503

(continued on following page)
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Table 4.1 continued
Methylation CPG Site 25

0.8394

24.8991

0.732

Methylation CPG Site 26

1.8252

24.2676

0.527

Methylation CPG Site 27

-0.0137

19.8429

0.563

Methylation CPG Site 28

0.5627

26.4499

0.579

Intercept

707.9339 42.2368

0.470

Variance of Error term = 402375.9, PD = 6.6218, DIC = 1405.477, Lambda = 120.5363

Table 4.1 reveals how the Bayesian LASSO method can be extended to the accelerated
failure time model beyond the survival regression and this extension is based on the least square
approximation (LSA) by Wang and Leng (2007). It can be observed from the table all of the
variables used in this study contribute significantly to the survival time of cancer patients and all
of them compute a high probability of being different from zero.

Figure 4.7 summarizes the coefficient of the methylation CPG site covariates 1 to 28 and
it can be observed that majority of the methylation CPG sites are significantly different from zero
as the plots wander up and down the zero line for majority of the coefficients. The methylation
CPG sites 3, 4,5,6,7,8,10,13,14,15,16,22,23,27 and 28 are the methylation covariates that are
identified to be significantly different from zero and therefore maintain a strong level of
relationship with the survival time of cancer patients. We can conclude that the genes associated
with the identified 15 CpG sites may affect the survival times in addition the significant covariates.
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Box plots of regression coefficients

Figure 4.7 Box plots of regression coefficient.

Figure 4.8 plots the mean square of the variance of error term against the 𝜆 parameter, and
as revealed by the sharp drop in the variance error term between 4.4 and 5.3, it can be concluded
that the model explains a substantial fraction of the variability in survival time of cancer patients;
specifically, the maximum proportion of variability explained is 65%.

The purpose of this research was to examine the relationship between the survival time of
cancer patients and the methylation CPG site obtained for 28 different categories as well as some
other demographic and clinical characteristics of 89 cancer patients, and it can be observed from
the analysis that there exists some relationship between some of methylation CPG site and the
survival time as the majority of the covariates are confirmed to be statistically different from zero,
which implies the methylation CPG site and other covariates employed in the analysis maintain a
substantial degree of relationship with the survival time of cancer patients.

39

log(Lambda)

Figure 4.8 Plot the mean square of the variance of error term against the 𝜆 parameter.

40

CHAPTER 5
CONCLUSION
This research combines the application of Bayesian regression method with the
Accelerated failure time model on cancer patients. The influence of some selected methylation
CPG site and demographic as well as clinical features of the patients on survival time measured in
days is investigated. Special attention focuses on the 28 different methylation CPG sites which are
investigated and are confirmed to be able to provide additional information in helping predict the
survival time of patients exposed to the same treatment and formulate a clinical outcome and
therapy guide for cancer patients.
5.1 The Bayesian LASSO Model
Many statistical techniques are based on the idea that any subject in a study sample can
be examined by any suitable statistical process. The Bayesian LASSO regression was generally
observed to be an appropriate statistical method when considering a sizeable amount of dataset
with complex pattern of relationship with an outcome. It uses only complete data quantities with
very simple rules of combination and this make the method especially attractive for observational
studies.
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5.1.1 Covariates Selection
The outcome of the statistical analysis revealed that all clinical and demographical
variables are significantly associated with the survival time, although the variable’s status shows
only moderate evidence of significance. The variable Smoke15 also shows a strong evidence of
association with the number of days survived.
A very important result revealed by this work is that the methylation CPG sites can be
independent predictors of cancer outcomes. The fitting results using the Bayesian LASSO
regression show a strong representation of the survival time. Seventeen out of the 28 methylation
CPG site covariates examined show a strong evidence of association with the outcome variable
(SurvDay). All of the 28 methylation CPG site covariates have been used as prognostic factors to
more accurately predict the clinical outcome and length of survival of cancer patients.
The survival probability at the mean for all of the covariates (clinical, demographic and
methylation CPG sites) for the number of days a patient will survive is obtained to be equal to
65%. Also, the decrease of survival proportion gets mild over time.
Conclusively, this research work provides some statistical indicators which are worthy of
further clinical research proof and clarification.
5.2 Limitations of the Study
Although the aim of this research has been achieved, there are some unavoidable
limitations in the course of the research work. First, due to the time constraint, this research was
conducted on only a small sample of cancer patients undergoing some clinical observation at the
time of the study; therefore, it might not be conventional to generalize the result of this research to
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a large population of cancer patients. Second, different geographical dispensation of the patients
might affect the result of the relationship between the methylation CPG sites and the survival time
which, is not included in the research due to limitations in accessing key information about the
patients.

5.3 Future Works
This research did not fully address the effect of proportional hazard since the focus was on
examining the posterior effect and finding the independent pattern of survival for cancer patients.
Some covariates were indeed time varying, and if the aim is to give a detailed description of the
covariate effects and to accurately calculate the predicted probabilities, then more flexible and
time-oriented models are needed in addition to with the model estimated in this research. The
selected covariates are likely not unique; therefore, further studies may focus on a special subset
of patient-specific markers. Some markers have demonstrated time-varying effects on outcomes.
Further and detailed checks of these time-varying effects, such as significant change on different
time periods, would be of much clinical interest. Also, using other windows of CpG sites, we may
explore genome-wide CpG sites and associated genes that affect the survival time of lung
adenocarcinoma patients.
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